» Articles » PMID: 22892452

Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced with Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC)

Overview
Journal J Immunother
Date 2012 Aug 16
PMID 22892452
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The fowl pox vector expressing the tumor-associated antigens, mucin-1 and carcinoembryonic antigen in the context of costimulatory molecules (rF-PANVAC) has shown promise as a tumor vaccine. However, vaccine-mediated expansion of suppressor T-cell populations may blunt clinical efficacy. We characterized the cellular immune response induced by ex vivo dendritic cells (DCs) transduced with (rF)-PANVAC. Consistent with the functional characteristics of potent antigen-presenting cells, rF-PANVAC-DCs demonstrated strong expression of mucin-1 and carcinoembryonic antigen and costimulatory molecules, CD80, CD86, and CD83; decreased levels of phosphorylated STAT3, and increased levels of Tyk2, Janus kinase 2, and STAT1. rF-PANVAC-DCs stimulated expansion of tumor antigen-specific T cells with potent cytolytic capacity. However, rF-PANVAC-transduced DCs also induced the concurrent expansion of FOXP3 expressing CD4CD25 regulatory T cells (Tregs) that inhibited T-cell activation. Moreover, Tregs expressed high levels of Th2 cytokines [interleukin (IL)-10, IL-4, IL-5, and IL-13] together with phosphorylated STAT3 and STAT6. In contrast, the vaccine-expanded Treg population expressed high levels of Th1 cytokines IL-2 and interferon-γ and the proinflammatory receptor-related orphan receptor γt (RORγt) and IL-17A suggesting that these cells may share effector functions with conventional TH17 T cells. These data suggest that Tregs expanded by rF-PANVAC-DCs, exhibit immunosuppressive properties potentially mediated by Th2 cytokines, but simultaneous expression of Th1 and Th17-associated factors suggests a high degree of plasticity.

Citing Articles

Cigarette Smoke and Morphine Promote Treg Plasticity to Th17 via Enhancing Trained Immunity.

Shao Y, Saaoud F, Cornwell W, Xu K, Kirchhoff A, Lu Y Cells. 2022; 11(18).

PMID: 36139385 PMC: 9497420. DOI: 10.3390/cells11182810.


Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis.

Escher T, Lui A, Geanes E, Walter K, Tawfik O, Hagan C Mol Cancer Res. 2019; 17(5):1180-1194.

PMID: 30655323 PMC: 6497545. DOI: 10.1158/1541-7786.MCR-18-0916.


A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Dillon P, Petroni G, Smolkin M, Brenin D, Chianese-Bullock K, Smith K J Immunother Cancer. 2017; 5(1):92.

PMID: 29157306 PMC: 5697108. DOI: 10.1186/s40425-017-0295-5.


Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.

Yu S, Ballas L, Skinner E, Dorff T, Sadeghi S, Quinn D Clin Adv Hematol Oncol. 2017; 15(7):543-551.

PMID: 28749918 PMC: 7523177.


Enhancing poxvirus vectors vaccine immunogenicity.

Garcia-Arriaza J, Esteban M Hum Vaccin Immunother. 2014; 10(8):2235-44.

PMID: 25424927 PMC: 4896794. DOI: 10.4161/hv.28974.


References
1.
Pantuck A, van Ophoven A, Gitlitz B, Tso C, Acres B, Squiban P . Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004; 27(3):240-53. DOI: 10.1097/00002371-200405000-00009. View

2.
Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A . Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203(7):1693-700. PMC: 2118333. DOI: 10.1084/jem.20060468. View

3.
Tokumasa N, Suto A, Kagami S, Furuta S, Hirose K, Watanabe N . Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood. 2007; 110(2):553-60. DOI: 10.1182/blood-2006-11-059246. View

4.
Zhou Q, Munger M, Highfill S, Tolar J, Weigel B, Riddle M . Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010; 116(14):2484-93. PMC: 2953885. DOI: 10.1182/blood-2010-03-275446. View

5.
Dannull J, Su Z, Rizzieri D, Yang B, Coleman D, Yancey D . Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005; 115(12):3623-33. PMC: 1288834. DOI: 10.1172/JCI25947. View